Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes

Endocrine

Volumn 52, Issue 3, 2016, Pages 458-480

  Bekiari, Eleni ^a   Rizava, Chrysoula ^a   Athanasiadou, Eleni ^a   Papatheodorou, Konstantinos ^a,b   Liakos, Aris ^a   Karagiannis, Thomas ^a   Mainou, Maria ^a   Rika, Maria ^a   Boura, Panagiota ^a   Tsapas, Apostolos ^a,c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

DPP 4 inhibitors; Meta analysis; Systematic review; Vildagliptin

Indexed keywords

ACARBOSE; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; NITRILE; PYRROLIDINE DERIVATIVE;

ADVERSE OUTCOME; ARTHRALGIA; ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DEATH; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; HYPOGLYCEMIA; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PRIORITY JOURNAL; RHINOPHARYNGITIS; RISK FACTOR; SKIN MANIFESTATION; SYSTEMATIC REVIEW; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; TREATMENT OUTCOME;

ADAMANTANE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; METFORMIN; NITRILES; PANCREATITIS; PYRROLIDINES; TREATMENT OUTCOME;

EID: 84952034474     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-015-0841-1     Document Type: Article

References (140)

1. International Diabetes Federation Diabetes Atlas (Sixth edition). https://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf. Accessed 17.11.2015
2. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A.L. Peters, A. Tsapas, R. Wender, D.R. Matthews, Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58(3), 429–442 (2015)
3. H. Park, C. Park, Y. Kim, K.L. Rascati, Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann. Pharmacother. 46(11), 1453–1469 (2012)
4. L. Cai, Y. Cai, Z.J. Lu, Y. Zhang, P. Liu, The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. J. Clin. Pharm. Ther. 37(4), 386–398 (2012)
5. A. Schweizer, S. Dejager, J.E. Foley, A. Couturier, M. Ligueros-Saylan, W. Kothny, Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes. Metab. 12(6), 485–494 (2010)
6. J. Higgins, S. Green. Missing standard deviations. In: Cochrane Handbook for Systematic Reviews of Interventions. p. 485. (2008)
7. M.J. Sweeting, A.J. Sutton, P.C. Lambert, What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat. Med. 23(9), 1351–1375 (2004)
8. J. Higgins, S. Green. Identifying and measuring heterogeneity. In: Cochrane Handbook for Systematic Reviews of Interventions. p. 277. (2008)
9. J. Rosenstock, S.W. Kim, M.A. Baron, R.P. Camisasca, F. Cressier, A. Couturier, S. Dejager, Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes. Metab. 9(2), 175–185 (2007)
10. D.A. D’Alessio, A.M. Denney, L.M. Hermiller, R.L. Prigeon, J.M. Martin, W.G. Tharp, M.L. Saylan, Y. He, B.E. Dunning, J.E. Foley, R.E. Pratley, Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 94(1), 81–88 (2009)
11. M. Diamant, M. Poelma, D.L. Goede, L.W. Van Golen, R.E. Van Genugten, E.M. Eekhoff, A. Schweizer, R.J. Heine, J.E. Foley, G. Nijpels, M.C. Bunck. One-year vildagliptin, compared to placebo, treatment does not affect markers of bone resorption and calcium homeostasis in drug-naive patients with type 2 diabetes and mild hyperglycemia. Paper presented at the The American Diabetes Association 70th Annual Scientific Sessions, Orlando, Florida
12. Y. Su, Y.L. Su, L.F. Lv, L.M. Wang, Q.Z. Li, Z.G. Zhao, Randomized controlled clinical trial of a combination therapy of vildagliptin plus an alpha-glucosidase inhibitor for patients with type II diabetes mellitus. Exp Ther Med 7(6), 1752–1756 (2014)
13. Y. Su, Y.L. Su, L.F. Lv, L.M. Wang, Q.Z. Li, Z.G. Zhao, A randomized controlled clinical trial of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus. Exp Ther Med 7(4), 799–803 (2014)
14. M. Takihata, A. Nakamura, Y. Terauchi, Comparative study of three DPP-4 inhibitors, namely sitagliptin, vildagliptin, and alogliptin, in Japanese type 2 diabetic patients: The COSVA randomized, controlled trial. Diabetes 63, A264 (2014)
15. C.J. Li, Q. Yu, P. Yu, Q.M. Zhang, M. Ding, X.J. Liu, D.M. Yu, Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 122(8), 469–476 (2014)
16. T. Forst, M. Dworak, C. Berndt-Zipfel, A. Loffler, I. Klamp, M. Mitry, A. Pfutzner, Effect of vildagliptin on postprandial proinsulin processing in the beta-cell of patients with type 2 diabetes mellitus. Diabetes 62, A568 (2013)
17. T. Forst, M. Dworak, C. Berndt-Zipfel, A. Loffler, I. Klamp, M. Mitry, A. Pfutzner, Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the beta cell of patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 15(6), 576–579 (2013)
18. C. Filozof, Corrigendum to A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet. Med. 30(5), 632 (2013)
19. G. Derosa, P.D. Ragonesi, A. Carbone, E. Fogari, A. D’Angelo, A.F. Cicero, P. Maffioli, Evaluation of the positive effects on insulin-resistance and beta-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients. Pharmacol. Res. 73, 20–26 (2013)
20. B. Bhandare, V. Satyanarayana, J. Adhikary, A comparative study to evaluate the efficacy and safety of Vildagliptin as an add-on therapy to a low-dose Metformin vs an uptitration of Metformin in type 2 DM patients. Int. J. Pharm. Sci. Rev. Res. 22(2), 116–120 (2013)
21. C. Berndt-Zipfel, G. Michelson, I. Klamp, M. Mitry, A. Pfutzner, T. Forst, Vildagliptin in addition to metformin improves retinal arteriolar wall to lumen ratio and erythrocyte flexibility in patients with type 2 diabetes mellitus. Diabetes 62, A156–A157 (2013)
22. C. Berndt-Zipfel, G. Michelson, M. Dworak, M. Mitry, A. Loffler, A. Pfutzner, T. Forst, Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus—results from an exploratory study. Cardiovasc. Diabetol. 12(1), 59 (2013)
23. M. Barbieri, M.R. Rizzo, R. Marfella, V. Boccardi, A. Esposito, A. Pansini, G. Paolisso, Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis 227(2), 349–354 (2013)
24. M. Abe, Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis. Blood Purif. 34(3–4), 261 (2013)
25. I. Zografou, C. Sampanis, A. Papageorgiou, B. Nikolaidou, P. Doukelis, D. Papadopoulou, M. Doumas, S. Douma, The combination therapy with metformin and vildagliptin decreases lymphocytes count in patients with type 2 diabetes mellitus. Diabetes 61, A600 (2012)
26. M.R. Rizzo, M. Barbieri, R. Marfella, G. Paolisso, Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 35(10), 2076–2082 (2012)
27. C. Pan, X. Xing, P. Han, S. Zheng, J. Ma, J. Liu, X. Lv, J. Lu, G. Bader, Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 14(8), 737–744 (2012)
28. V. Lukashevich, M. Wang, S. Del Prato, M. Araga, W. Kothny, Vildagliptin efficacy and safety in patients with type 2 diabetes inadequately controlled on dual metformin plus sulfonylurea therapy. Diabetologia 55, S353 (2012)
29. V. Lukashevich, P. Kozlovski, J. Foley, W. Kothny, Vildagliptin combined with insulin reduces HBA1C without increasing risk of hypoglycemia and weight gain in patients with type 2 diabetes mellitus. Diabetes 61, A254 (2012)
30. P. Kozlovski, J. Foley, Q. Shao, V. Lukashevich, W. Kothny, Improved glycaemic control without increased hypoglycaemia incidence and weight gain with insulin-vildagliptin combination therapy in Asian patients with type 2 diabetes. Diabetologia 55, S355 (2012)
31. W. Kothny, M. Wang, Q. Shao, P.H. Groop, V. Lukashevich, One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes mellitus and moderate or severe renal insufficiency. Diabetes 61, A253 (2012)
32. W. Kothny, Q. Shao, P.H. Groop, V. Lukashevich, One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes. Metab. 14(11), 1032–1039 (2012)
33. W. Kothny, P. Kozlovski, J. Foley, Q. Shao, V. Lukashevich, Vildagliptin added to once or twice daily insulin regimens improves glycaemic control without increasing risk of hypoglycaemia and weight gain in patients with type 2 diabetes. Diabetologia 55, S354 (2012)
34. N.H. Kim, Y.A. Sung, C.W. Ahn, S.W. Park, S. Lim, C.H. Kim, D.S. Kim, Y.G. Shin, K.J. Ahn, J.H. Kim, S.H. Baik, Efficacy and safety of add-on vildagliptin to metformin in comparison to uptitrating metformin therapy. Diabetes 61, A297 (2012)
35. H. Gilet, J.B. Gruenberger, G. Bader, M. Viala-Danten, Demonstrating the burden of hypoglycemia on patients’ quality of life in diabetes clinical trials: measurement considerations for hypoglycemia. Value Health 15(8), 1036–1041 (2012)
36. J. Foley, P. Kozlovski, V. Lukashevich, W. Kothny, Vildagliptin improves a chronic effect on beta cell function when added to insulin therapy. Diabetologia 55, S355 (2012)
37. G. Derosa, P.D. Ragonesi, A. Carbone, E. Fogari, A. D’Angelo, A.F. Cicero, P. Maffioli, Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. Expert Opin. Pharmacother. 13(18), 2581–2591 (2012)
38. G. Derosa, P.D. Ragonesi, A. Carbone, E. Fogari, L. Bianchi, A. Bonaventura, D. Romano, A.F. Cicero, P. Maffioli, Vildagliptin added to metformin on beta-cell function after an euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetic patients. Diabetes 61, A596 (2012)
39. G. Derosa, P.D. Ragonesi, A. Carbone, E. Fogari, L. Bianchi, A. Bonaventura, D. Romano, A.F. Cicero, P. Maffioli, Vildagliptin added to metformin on beta-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. Diabetes Technol Ther 14(6), 475–484 (2012)
40. M.C. Bunck, M. Poelma, E.M. Eekhoff, A. Schweizer, R.J. Heine, G. Nijpels, J.E. Foley, M. Diamant, Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients. J Diabetes 4(2), 181–185 (2012)
41. V. Lukashevich, A. Schweizer, Q. Shao, P.H. Groop, W. Kothny, Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes. Metab. 13(10), 947–954 (2011)
42. V. Lukashevich, A. Schweizer, J. Foley, Q. Shao, P.H. Groop, W. Kothny, Efficacy of vildagliptin therapy in combination with insulin in patients with type 2 diabetes and severe renal impairment. Diabetologia 54, S332–S333 (2011)
43. W. Kothny, A. Schweizer, R. Naik, P.H. Groop, Q. Shao, V. Lukashevich, Comparison of vildagliptin with placebo in a 24-week study of 221 patients with type 2 diabetes and severe renal impairment (eGFR < 30). Diabetologia 54, S332 (2011)
44. H.J. Jeon, T.K. Oh, Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients. Diabetes Metab J 35(5), 529–535 (2011)
45. M. Ito, M. Abe, K. Okada, H. Sasaki, N. Maruyama, M. Tsuchida, T. Higuchi, F. Kikuchi, M. Soma, The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr. J. 58(11), 979–987 (2011)
46. J.B. Gruenberger, H. Gilet, L. Esteve, M. Viala-Danten, Association of patient-reported hypoglycemia with health-related quality of life (HRQL) in type 2 diabetes (T2D) patients: results from a clinical trial. Diabetes 60, A549 (2011)
47. J.E. Foley, M.C. Bunck, D.L. Moller-Goede, M. Poelma, G. Nijpels, E.M. Eekhoff, A. Schweizer, R.J. Heine, M. Diamant, Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia 54(8), 1985–1991 (2011)
48. D.R. Matthews, S. Dejager, B. Ahren, V. Fonseca, E. Ferrannini, A. Couturier, J.E. Foley, B. Zinman, Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes. Metab. 12(9), 780–789 (2010)
49. M. Kikuchi, M. Haneda, D. Koya, K. Tobe, Y. Onishi, A. Couturier, N. Mimori, Y. Inaba, M. Goodman, Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 89(3), 216–223 (2010)
50. Y. Iwamoto, A. Kashiwagi, N. Yamada, S. Terao, N. Mimori, M. Suzuki, H. Tachibana, Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. Diabetes Obes. Metab. 12(8), 700–708 (2010)
51. C. Filozof, S. Schwartz, J.E. Foley, Effect of vildagliptin as add-on therapy to a low-dose metformin. World J. Diabetes 1(1), 19–26 (2010)
52. C. Filozof, J.F. Gautier, A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet. Med. 27(3), 318–326 (2010)
53. M.A. Banerji, D. Purkayastha, B.H. Francis, Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study. Diabetes Res. Clin. Pract. 90(2), 182–190 (2010)
54. B. Ahren, J.E. Foley, E. Ferrannini, D.R. Matthews, B. Zinman, S. Dejager, V.A. Fonseca, Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 33(4), 730–732 (2010)
55. A. Schweizer, S. Dejager, E. Bosi, Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes. Metab. 11(8), 804–812 (2009)
56. J. Rosenstock, M. Niggli, M. Maldonado-Lutomirsky, Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 11(6), 571–578 (2009)
57. J.J. Meier, M. Vollmer, C. Pennartz, C. Abletshauser, W.E. Schmidt, Efficacy and safety of early combination of vildagliptin and metformin in comparison to placebo in patients with type 2 diabetes. Diabetologia 52(S1), S304 (2009)
58. M. Kikuchi, N. Abe, M. Kato, S. Terao, N. Mimori, H. Tachibana, Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 83(2), 233–240 (2009)
59. M. Goodman, H. Thurston, J. Penman, Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm. Metab. Res. 41(5), 368–373 (2009)
60. B. Francis, D. Purkayastha, M.A. Banerji, Safety of vildagliptin in patients with mild renal impairment and patients with normal renal function: GALIANT study. Can. J. Diabetes 33(3), 288–289 (2009)
61. J.E. Foley, S. Sreenan, Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm. Metab. Res. 41(12), 905–909 (2009)
62. J.E. Foley, S.S. Efficacy, Erratum: safety comparison between the dpp-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm. Metab. Res. 41(12), 909 (2009)
63. E. Ferrannini, V. Fonseca, B. Zinman, D. Matthews, B. Ahren, S. Byiers, Q. Shao, S. Dejager, Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes. Metab. 11(2), 157–166 (2009)
64. E. Bosi, F. Dotta, Y. Jia, M. Goodman, Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 11(5), 506–515 (2009)
65. G. Bolli, F. Dotta, L. Colin, B. Minic, M. Goodman, Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes. Metab. 11(6), 589–595 (2009)
66. L. Blonde, S. Dagogo-Jack, M.A. Banerji, R.E. Pratley, A. Marcellari, R. Braceras, D. Purkayastha, M. Baron, Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial-a primary care, type 2 diabetes study. Diabetes Obes. Metab. 11(10), 978–986 (2009)
67. B. Ahren, J. Foley, E. Ferrannini, D. Matthews, B. Zinman, S. Dejager, V. Fonseca, Changes in prandial glucagon levels after 2 years treatment with vildagliptin or glimepiride. Diabetologia 52(S1), S314 (2009)
68. W.A. Scherbaum, A. Schweizer, A. Mari, P.M. Nilsson, G. Lalanne, Y. Wang, B.E. Dunning, J.E. Foley, Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes. Metab. 10(11), 1114–1124 (2008)
69. W.A. Scherbaum, A. Schweizer, A. Mari, P.M. Nilsson, G. Lalanne, S. Jauffret, J.E. Foley, Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes. Metab. 10(8), 675–682 (2008)
70. C. Pan, W. Yang, J.P. Barona, Y. Wang, M. Niggli, P. Mohideen, Y. Wang, J.E. Foley, Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet. Med. 25(4), 435–441 (2008)
71. A. Mari, W.A. Scherbaum, P.M. Nilsson, G. Lalanne, A. Schweizer, B.E. Dunning, S. Jauffret, J.E. Foley, Characterization of the influence of vildagliptin on model-assessed beta-cell function in patients with type 2 diabetes and mild hyperglycemia. J. Clin. Endocrinol. Metab. 93(1), 103–109 (2008)
72. B. Goke, K. Hershon, D. Kerr, A. Calle Pascual, A. Schweizer, J. Foley, Q. Shao, S. Dejager, Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm. Metab. Res. 40(12), 892–895 (2008)
73. A.J. Garber, J.E. Foley, M.A. Banerji, P. Ebeling, S. Gudbjornsdottir, R.P. Camisasca, A. Couturier, M.A. Baron, Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes. Metab. 10(11), 1047–1056 (2008)
74. G. Bolli, F. Dotta, E. Rochotte, S.E. Cohen, Efficacy and tolerability of vildagliptin vs pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes. Metab. 10(1), 82–90 (2008)
75. A. Schweizer, A. Couturier, J.E. Foley, S. Dejager, Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabet. Med. 24(9), 955–961 (2007)
76. F.X. Pi-Sunyer, A. Schweizer, D. Mills, S. Dejager, Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res. Clin. Pract. 76(1), 132–138 (2007)
77. A.J. Garber, A. Schweizer, M.A. Baron, E. Rochotte, S. Dejager, Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes. Metab. 9(2), 166–174 (2007)
78. V. Fonseca, A. Schweizer, D. Albrecht, M.A. Baron, I. Chang, S. Dejager, Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 50(6), 1148–1155 (2007)
79. S. Dejager, S. Razac, J.E. Foley, A. Schweizer, Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm. Metab. Res. 39(3), 218–223 (2007)
80. E. Bosi, R.P. Camisasca, C. Collober, E. Rochotte, A.J. Garber, Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 30(4), 890–895 (2007)
81. B. Ahren, G. Pacini, A. Tura, J.E. Foley, A. Schweizer, Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Horm. Metab. Res. 39(11), 826–829 (2007)
82. R.E. Pratley, S. Jauffret-Kamel, E. Galbreath, D. Holmes, Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm. Metab. Res. 38(6), 423–428 (2006)
83. S. Ristic, S. Byiers, J. Foley, D. Holmes, Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes. Metab. 7(6), 692–698 (2005)
84. B. Ahren, G. Pacini, J.E. Foley, A. Schweizer, Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 28(8), 1936–1940 (2005)
85. B. Ahren, R. Gomis, E. Standl, D. Mills, A. Schweizer, Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27(12), 2874–2880 (2004)
86. B. Ahren, J.E. Foley, S. Dejager, M. Akacha, Q. Shao, G. Heimann, M. Dworak, A. Schweizer, Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities? Diabetes Ther 5(2), 459–469 (2014)
87. M.C. Bunck, M. Poelma, D.L. Goede, L.W. Van Golen, R.E. Van Genugten, E.M. Eekhoff, A. Schweizer, R.J. Heine, J.E. Foley, G. Nijpels, M. Diamant. Beta-cell function and glycemic control following one-year vildagliptin treatment, and after 12-week washout, in drug-naive patients with type 2 diabetes and mild hyperglycemia. Paper presented at the The American Diabetes Association 70th Annual Scientific Sessions, Orlando, Florida
88. W. David Strain, V. Lukashevich, W. Kothny, M.J. Hoellinger, P. Paldanius, INdividualised Treatment targets for EldeRly patients using Vildagliptin Add-on or Lone therapy (INTERVAL) study. Diabetologia 56, S354–S355 (2013)
89. W.L. de Ranitz-Greven, J.W. Beulens, L.B. Hoeks, G. Belle-van Meerkerk, D.H. Biesma, H.W. de Valk, Patients with type 2 diabetes mellitus failing on oral agents and starting once daily insulin regimen; a small randomized study investigating effects of adding vildagliptin. BMC Res Notes 7, 579 (2014)
90. G. Derosa, A. Bonaventura, L. Bianchi, D. Romano, E. Fogari, A. D’Angelo, P. Maffioli, Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. Metab. Clin. Exp. 63(7), 957–967 (2014)
91. G. Derosa, A. Bonaventura, L. Bianchi, D. Romano, E. Fogari, A. D’Angelo, P. Maffioli, Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with Type 2 diabetes. Diabet. Med. 31(12), 1515–1523 (2014)
92. M. Hassanein, K. Abdallah, A. Schweizer, A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Vasc. Health Risk Manag. 10, 319–326 (2014)
93. W. Kothny, J. Foley, A. Schweizer, M.S. Rendell, V. Lukashevich, Efficacy of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment. Diabetologia 57, S357–S358 (2014)
94. V. Lukashevich, S.D. Prato, M. Araga, W. Kothny, Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes. Metab. 16(5), 403–409 (2014)
95. P. Maffioli, A. Bonaventura, L. Bianchi, D. Romano, E. Fogari, A. D’Angelo, G. Derosa, Comparison of vildagliptin and glimepiride: effects on glycemic control, fat tolerance, and inflammatory markers in people with type 2 diabetes. Diabetes 63, A277 (2014)
96. M. Odawara, I. Hamada, M. Suzuki, Efficacy and safety of vildagliptin as add-on to metformin in japanese patients with type 2 diabetes mellitus. Diabetes Ther 5(1), 169–181 (2014)
97. H.J. Strotmann, D. Goetze, C. Koch, T. Forst, Vildagliptin versus insulin as add-on therapy to glimepiride in type 2 diabetes mellitus: results from a randomised controlled trial. Diabetologia 1, S364–S365 (2014)
98. G. Ning, W. Wang, L. Li, J. Ma, X. Lv, M. Yang, W. Wang, M. Woloschak, V. Lukashevich, W. Kothny, Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus. J. Diabetes (2015). doi:10.1111/1753-0407.12303
99. W. Yang, X. Xing, X. Lv, Y. Li, J. Ma, G. Yuan, F. Sun, W. Wang, M. Woloschak, V. Lukashevich, P. Kozlovski, W. Kothny, Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus. J. Diabetes 7(2), 174–181 (2015)
100. T. Forst, C. Koch, M. Dworak, Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study. Curr. Med. Res. Opin. 31(6), 1079–1084 (2015)
101. A.R. Hong, J. Lee, E.J. Ku, Y. Hwangbo, K.M. Kim, J.H. Moon, S.H. Choi, H.C. Jang, S. Lim, Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): a randomized trial. Diabetes Res. Clin. Pract. 109(1), 141–148 (2015)
102. M. Macauley, K.G. Hollingsworth, F.E. Smith, P.E. Thelwall, A. Al-Mrabeh, A. Schweizer, J.E. Foley, R. Taylor, Effect of vildagliptin on hepatic steatosis. J. Clin. Endocrinol. Metab. 100(4), 1578–1585 (2015)
103. Y. Takeshita, T. Takamura, Y. Kita, T. Otoda, K.I. Kato, H. Wakakuri, M. Yamada, H. Misu, Y. Matsushima, S. Kaneko, Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study. J. Diabetes Investig. 6(2), 192–200 (2015)
104. I. Zografou, C. Sampanis, E. Gkaliagkousi, F. Iliadis, A. Papageorgiou, P. Doukelis, K. Vogiatzis, S. Douma, Effect of vildagliptin on hsCRP and arterial stiffness in patients with type 2 diabetes mellitus. Hormones 14(1), 118–125 (2015)
105. A. Strozik, A. Steposz, M. Basiak, M. Drozdz, B. Okopien, Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus. Pharmacol. Rep. 67(1), 24–31 (2015)
106. G. Ning, L. Li, J. Ma, X. Lv, M. Yang, W. Wang, M. Woloschak, V. Lukashevich, W. Kothny, Vildagliptin as add-on to insulin improves glycaemic control without increased risk of hypoglycaemia in Asian (predominantly Chinese) patients with type 2 diabetes mellitus. Diabetologia 57, S330 (2014)
107. CLAF237A1303. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=2490. Accessed 18 June 2015
108. CLAF237A2205. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=1475
109. CLAF237A2329. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=2297
110. CLAF237A23118. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=9563. Accessed 18 June 2015
111. CLAF237AFR03. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=7283. Accessed 18 June 2015
112. CLAF237B2224. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=9923. Accessed 18 June 2015
113. CLAF237A23155. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=11764. Accessed 18 June 2015
114. CLAF237B2201. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=4586. Accessed 18 June 2015
115. CLAF237A23138. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=4599. Accessed 18 June 2015
116. W. Kothny, V. Lukashevich, J.E. Foley, M.S. Rendell, A. Schweizer, Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial. Diabetologia 58(9), 2020–2026 (2015)
117. CLAF237A23154. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=10803. Accessed 18 June 2015
118. C.J. Li, X.J. Liu, L. Bai, Q. Yu, Q.M. Zhang, P. Yu, D.M. Yu, Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents. Diabetol. Metab. Syndr. 6(1), 69 (2014)
119. J. Rosenstock, M.A. Baron, S. Dejager, D. Mills, A. Schweizer, Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 30(2), 217–223 (2007)
120. J. Rosenstock, M.A. Baron, S. Dejager, D. Mills, A. Schweizer, Erratum: comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: A 24-week, double-blind, randomized trial (Diabetes Care (2007) 30 (217–223)). Diabetes Care 30(5), 1330 (2007)
121. W. Kothny, J. Foley, P. Kozlovski, Q. Shao, B. Gallwitz, V. Lukashevich, Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 15(3), 252–257 (2013)
122. A. Strozik, A. Steposz, B. Okopien, Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus. Diabetes 62, A668 (2013)
123. I. Zografou, C. Sampanis, A. Papageorgiou, B. Nikolaidou, P. Doukelis, D. Papadopoulou, M. Doumas, S. Douma, The effect of vildagliptin on arterial stiffness in drug naive patients with type 2 diabetes mellitus. Diabetes 62, A596 (2013)
124. M. Haidinger, J. Werzowa, M. Hecking, M. Antlanger, G. Stemer, J. Pleiner, C. Kopecky, J.J. Kovarik, D. Doller, G. Pacini, M.D. Saemann, Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation-a randomized, double-blind, placebo-controlled trial. Am. J. Trans. 14(1), 115–123 (2014)
125. M. Haidinger, J. Werzowa, M. Hecking, G. Stemer, J. Pleiner, C. Kopecky, G. Pacini, M. Antlanger, M.D. Saemann, Vildagliptin in new-onset diabetes after kidney transplantation is safe and efficencient-results from the viennavinodat trial. Nephrol. Dial. Trans. 28, i77 (2013)
126. M. Haidinger, J. Werzowa, M. Hecking, G. Pacini, M. Antlanger, J. Kovarik, Efficacy and safety of vildagliptin in newly diagnosed diabetes after kidney transplantation: results from the Vienna VINODAT trial. Wien. Klin. Wochenschr. 25, S19–S20 (2013)
127. M. Haidinger, J. Werzowa, H.C. Voigt, J. Pleiner, G. Stemer, M. Hecking, D. Doller, W.H. Horl, T. Weichhart, M.D. Saemann, A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation. Trials 11, 91 (2010)
128. W.D. Strain, V. Lukashevich, W. Kothny, M.J. Hoellinger, P.M. Paldanius, Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet 382(9890), 409–416 (2013)
129. CLAF237A23138E1. http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=5923. Accessed 18 June 2015
130. FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. http://www.fda.gov/Drugs/DrugSafety/ucm459579.htm (2015). Accessed 29 August 2015
131. J.B. Green, M.A. Bethel, P.W. Armstrong, J.B. Buse, S.S. Engel, J. Garg, R. Josse, K.D. Kaufman, J. Koglin, S. Korn, J.M. Lachin, D.K. McGuire, M.J. Pencina, E. Standl, P.P. Stein, S. Suryawanshi, F. Van de Werf, E.D. Peterson, R.R. Holman, Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. (2015). doi:10.1056/NEJMoa1501352
132. B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, B. Hirshberg, P. Ohman, R. Frederich, S.D. Wiviott, E.B. Hoffman, M.A. Cavender, J.A. Udell, N.R. Desai, O. Mosenzon, D.K. McGuire, K.K. Ray, L.A. Leiter, I. Raz, Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369(14), 1317–1326 (2013)
133. W.B. White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Bergenstal, G.L. Bakris, A.T. Perez, P.R. Fleck, C.R. Mehta, S. Kupfer, C. Wilson, W.C. Cushman, F. Zannad, Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 369(14), 1327–1335 (2013)
134. D.R. Matthews, A. Tsapas, Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes. Diabetes Vasc. Dis. Res. 5(3), 216–218 (2008)
135. K. Krum, V. Lukashevich, G.B. Bolli, P. Kozlovski, W. Kothny, P. Ponikowski. No Significant Difference in Risk of Heart Failure Hospitalization with Vildagliptin in Diabetic Patients with Systolic Chronic Heart Failure: VIVIDD. Paper presented at the The American Diabetes Association 74th Annual Scientific Sessions, San Francisco, California, June 13–17
136. J. McMurray. The vildagliptin in ventricular dysfunction diabetes (VIVIDD) trial. Paper presented at the Heart Failure Congress, Lisbon, Portugal, May 25–28
137. M. Evans, G. McInnes, M. Stumvoll, S. Del Prato, A. Schweizer, Q. Shao, V. Lukashevich, W. Kothny, Assessment of heart failure risk with vildagliptin in diabetic patients: pooled analysis of safety data from approximately 17,000 patients. Diabetologia 57(1 SUPPL. 1), S361 (2014)
138. M. Monami, I. Dicembrini, E. Mannucci, Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr. Metab. Cardiovasc. Dis. 24(7), 689–697 (2014)
139. G. McInnes, M. Evans, S. Del Prato, M. Stumvoll, A. Schweizer, V. Lukashevich, Q. Shao, W. Kothny. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17000 patients. Diabetes Obes Metab (2015)
140. Guidance for Industry Diabetes Mellitus—Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. In: Services, U.S.D.o.H.a.H. (ed.) Federal Register: The daily journal of the United States Government, vol. 18 June 2015. (Food and Drug Administration, 2008)